← Back to Search

Checkpoint Inhibitor

Nivolumab + Radium-223 for Prostate Cancer (Rad2Nivo Trial)

Phase 1 & 2
Recruiting
Led By Benjamin Maughan, MD, PharmD
Research Sponsored by University of Utah
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Estimated creatinine clearance ≥ 30 mL/min by Cockcroft-Gault formula: Males: ((140-age)×weight[kg])/(serum creatinine [mg/dL]×72)
Histologically confirmed adenocarcinoma of the prostate
Timeline
Screening 3 weeks
Treatment Varies
Follow Up between baseline and c4d15 (about 5 months)
Awards & highlights

Rad2Nivo Trial Summary

This trial is testing a new safety drug in two phases. First, a small group of people will test it to make sure it's safe. If it is, then a larger group of people will use it.

Who is the study for?
This trial is for men over 18 with advanced prostate cancer that has spread to the bones but not to other organs. They must have a certain white blood cell count, hemoglobin level, and liver function; no severe side effects from previous treatments; controlled testosterone levels; and be in fairly good health overall. Men who can father children must use effective birth control.Check my eligibility
What is being tested?
The study tests Nivolumab combined with Radium-223 in an open-label setup where everyone knows what treatment they're getting. It starts with a safety check phase followed by a larger test phase to see how well it works for bone metastasis in prostate cancer.See study design
What are the potential side effects?
Potential side effects of Nivolumab may include immune system reactions affecting different parts of the body, fatigue, skin issues, digestive problems, and infusion-related reactions. The specific side effects related to Radium-223 are not listed but typically could include nausea, diarrhea, or bone marrow suppression.

Rad2Nivo Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
My kidneys are functioning well enough for treatment.
Select...
My prostate cancer was confirmed through a tissue examination.
Select...
I am a man aged 18 or older.
Select...
My prostate cancer has spread and is resistant to hormone therapy, but it hasn't spread to my internal organs.
Select...
I can take care of myself but might not be able to do heavy physical work.
Select...
My testosterone levels are below 50 ng/dL.
Select...
My doctor says my cancer has spread to my bones and is causing symptoms.

Rad2Nivo Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~between baseline and c4d15 (about 5 months)
This trial's timeline: 3 weeks for screening, Varies for treatment, and between baseline and c4d15 (about 5 months) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Phase II: To assess the ctDNA reduction after 6 weeks of nivolumab treatment.
Phase Ib:To assess the safety of nivolumab in combination w Radium-223 in patients w metastatic castrate resistant prostate cancer.
Secondary outcome measures
To assess PSA progression free survival defined by the Prostate Cancer Working Group 3 (PCWG3).
To assess correlation of bone metabolism markers with clinical response.
To assess radiographic progression-free survival as defined by the PCWG3 criteria.
+2 more

Side effects data

From 2022 Phase 3 trial • 541 Patients • NCT02041533
57%
Nausea
54%
Anaemia
51%
Fatigue
39%
Decreased appetite
36%
Malignant neoplasm progression
32%
Constipation
31%
Diarrhoea
30%
Cough
29%
Vomiting
29%
Dyspnoea
25%
Oedema peripheral
24%
Back pain
21%
Pyrexia
21%
Neutropenia
19%
Headache
19%
Hypomagnesaemia
18%
Arthralgia
16%
Asthenia
16%
Dizziness
16%
Neutrophil count decreased
15%
Thrombocytopenia
15%
Insomnia
14%
Hyponatraemia
14%
Rash
14%
Weight decreased
14%
Platelet count decreased
13%
Blood creatinine increased
13%
White blood cell count decreased
12%
Hypokalaemia
12%
Pruritus
12%
Abdominal pain
12%
Pain in extremity
11%
Myalgia
11%
Alanine aminotransferase increased
11%
Aspartate aminotransferase increased
10%
Alopecia
10%
Hypoalbuminaemia
10%
Muscular weakness
10%
Dry skin
10%
Chest pain
10%
Dysgeusia
10%
Pneumonia
10%
Productive cough
9%
Abdominal pain upper
9%
Upper respiratory tract infection
9%
Hypothyroidism
9%
Mucosal inflammation
9%
Peripheral sensory neuropathy
8%
Nasopharyngitis
8%
Lacrimation increased
8%
Non-cardiac chest pain
8%
Epistaxis
8%
Haemoptysis
8%
Stomatitis
8%
Dysphonia
7%
Chills
7%
Hyperkalaemia
7%
Hypertension
7%
Bronchitis
7%
Dehydration
7%
Blood alkaline phosphatase increased
7%
Hyperglycaemia
7%
Lymphocyte count decreased
7%
Anxiety
6%
Hypophosphataemia
6%
Leukopenia
6%
Pleural effusion
6%
Neuropathy peripheral
6%
Pneumonitis
6%
Oropharyngeal pain
5%
Hypotension
5%
Pain
5%
Malaise
5%
Musculoskeletal chest pain
5%
Rash maculo-papular
5%
Dry mouth
5%
Urinary tract infection
5%
Dyspepsia
5%
Gamma-glutamyltransferase increased
5%
Depression
5%
Muscle spasms
4%
Fall
4%
Pulmonary embolism
3%
Metastases to central nervous system
3%
Myocardial infarction
3%
Febrile neutropenia
3%
Musculoskeletal pain
3%
Chronic obstructive pulmonary disease
2%
Sepsis
2%
Malignant pleural effusion
2%
General physical health deterioration
2%
Adrenal insufficiency
2%
Atrial fibrillation
2%
Cardiac failure
2%
Embolism
1%
Pneumothorax
1%
Atrial flutter
1%
Bone pain
1%
Small intestinal haemorrhage
1%
Bronchial obstruction
1%
Femur fracture
1%
Syncope
1%
Hypercalcaemia
1%
Pericardial effusion malignant
1%
Confusional state
1%
Cancer pain
1%
Neoplasm progression
1%
Circulatory collapse
1%
Superior vena cava syndrome
1%
Performance status decreased
1%
Pancytopenia
1%
Colitis
1%
Pericardial effusion
1%
Gastrointestinal haemorrhage
1%
Ileus
1%
Small intestinal obstruction
1%
Lung cancer metastatic
1%
Respiratory tract infection
1%
Respiratory failure
1%
Tumour pain
1%
Appendicitis
1%
Skin infection
1%
Ataxia
1%
Seizure
100%
80%
60%
40%
20%
0%
Study treatment Arm
Investigator Choice of Chemotherapy
Post Chemotherapy Optional Nivolumab
Nivolumab

Rad2Nivo Trial Design

1Treatment groups
Experimental Treatment
Group I: Treatment: all patientsExperimental Treatment1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Nivolumab
2014
Completed Phase 3
~4750

Find a Location

Who is running the clinical trial?

University of UtahLead Sponsor
1,104 Previous Clinical Trials
1,782,497 Total Patients Enrolled
8 Trials studying Prostate Cancer
5,349 Patients Enrolled for Prostate Cancer
Benjamin Maughan, MD, PharmDPrincipal InvestigatorHuntsman Cancer Institute

Media Library

Nivolumab (Checkpoint Inhibitor) Clinical Trial Eligibility Overview. Trial Name: NCT04109729 — Phase 1 & 2
Prostate Cancer Research Study Groups: Treatment: all patients
Prostate Cancer Clinical Trial 2023: Nivolumab Highlights & Side Effects. Trial Name: NCT04109729 — Phase 1 & 2
Nivolumab (Checkpoint Inhibitor) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04109729 — Phase 1 & 2
~8 spots leftby May 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top